drugset / Trial / NCT01271439
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
Phase 2
Completed
60 enrolled
Sun Yat-sen University
Affiliated Cancer Hospital of Shantou University Medical College · collabFirst Affiliated Hospital of Guangxi Medical University · collabFirst People's Hospital of Foshan · collabHubei Cancer Hospital · collabHunan Cancer Hospital · collabJiangxi Provincial Cancer Hospital · collabShenzhen People's Hospital · collabTongji University · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collabWenzhou Medical University · collabWuhan University · collabXijing Hospital · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy in advanced T stage of nasopharyngeal carcinoma. Besides, to figure out the relationship between patient outcome and EGFR gene copy number, expression and mutation.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-06
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |